Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of riliprubart versus IVIg in chronic inflammatory demyelinating polyneuropathy
2023-508338-33-00Phase 3Authorised
- Sponsor
- Sanofi
- Start
- Oct 2024
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial of riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP) (2 arms), sponsored by Sanofi. Primary endpoints: Percentage of participants experiencing a response and Percentage of participants randomized to riliprubart who responded during Part A and had a lasting response during the open-label treatment extension period. Planned start Oct 2024; status: authorised.
02
Drugs
riliprubart
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on 2023-508338-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508338-33-00.